Targeting PIM kinase activity significantly augments the efficacy of cytarabine.

Kelly KR; Espitia CM; Taverna P; Choy G; Padmanabhan S; Nawrocki ST; Giles FJ; Carew JS

首页> 外文期刊>British Journal of Haematology >Targeting PIM kinase activity significantly augments the efficacy of cytarabine.

【24h】

Targeting PIM kinase activity significantly augments the efficacy of cytarabine.

机译：靶向PIM激酶活性可显着提高阿糖胞苷的疗效。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Drug resistance is a major cause of treatment failure for patients with acute myeloid leukaemia (AML) and novel strategies that circumvent resistance mechanisms are urgently needed (Swords et al, 2010). The PIM kinases (PIM1, PIM2, PIM3) are a small family of proto-oncogenes within the CAMK superfamily that are frequently overexpressed in many forms of cancer including AML. PIM kinases have essential roles in the regulation of signal transduction cascades that promote cell survival, proliferation, and drug resistance (Amaravadi & Thompson, 2005; Giles, 2005; Nawijn et al, 2011).

机译：耐药性是急性髓细胞性白血病（AML）患者治疗失败的主要原因，因此迫切需要一种新的策略来规避耐药性（Swords等，2010）。 PIM激酶（PIM1，PIM2，PIM3）是CAMK超家族中的一小类原癌基因家族，在许多形式的癌症（包括AML）中经常过表达。 PIM激酶在促进细胞存活，增殖和耐药性的信号转导级联反应的调控中起着至关重要的作用（Amaravadi＆Thompson，2005; Giles，2005; Nawijn等，2011）。

著录项

来源
《British Journal of Haematology》 |2012年第1期|共4页
作者
Kelly KR; Espitia CM; Taverna P; Choy G; Padmanabhan S; Nawrocki ST; Giles FJ; Carew JS;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Targeting PIM kinase activity significantly augments the efficacy of cytarabine. [J] . Kelly KR, Espitia CM, Taverna P, British Journal of Haematology . 2012,第1期

机译：靶向PIM激酶活性可显着提高阿糖胞苷的疗效。
2. Multiple Growth Factor Targeting by Engineered Insulin-like Growth Factor Binding Protein-3 Augments EGF Receptor Tyrosine Kinase Inhibitor Efficacy [J] . Elizabeth A. Wang, Wan-Yu Chen, Chi-Huey Wong Scientific reports. . 2020,第1期

机译：通过工程胰岛素样生长因子结合蛋白-3增强EGF受体酪氨酸激酶抑制剂疗效的多种生长因子靶向
3. 63 Efficacy evaluation of novel Pim kinase inhibitors with anticancer activity [J] . K. Brzozka, A. Zarebski, R. Windak, European Journal of Cancer Supplements . 2010,第7期

机译：63具有抗癌活性的新型Pim激酶抑制剂的疗效评估
4. Kinase Activity Profiling of Lung Adenocarcinoma to Understand Cancer Signaling and Select Targeted Therapeutics [C] . Melissa A. Hoffman, Bin Fang, Stephen Brantley, ASMS Conference on Mass Spectrometry and Allied Topics . 2016

机译：肺腺癌的激酶活性分析，了解癌症信号，选择有针对性的治疗方法
5. Integrating genomics and molecular biology: identifying transcriptional targets for the prostate cancer oncogene SOX4 and evaluating the efficacy of Aurora kinase inhibition in chemotherapy-resistant ovarian cancer [D] . Scharer, Christopher D. 2009

机译：整合基因组学和分子生物学：鉴定前列腺癌致癌基因SOX4的转录靶标并评估Aurora激酶抑制作用对化疗耐药的卵巢癌的疗效
6. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma [O] . D Mahalingam, C M Espitia, E C Medina, 2011

机译：靶向PIM激酶增强舒尼替尼在肾细胞癌中的活性
7. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells [O] . Martinelli Erika, Troiani Teresa, DAiuto Elena, 2013

机译：pimasertib（一种选择性的MEK 1/2抑制剂）与PI3K / mTOR抑制剂或多靶点激酶抑制剂联合在耐pimasertib的人肺癌和大肠癌细胞中的抗肿瘤活性

Targeting PIM kinase activity significantly augments the efficacy of cytarabine.

摘要

著录项

相似文献

相关主题

期刊订阅